



Potential impacts on pesticides industry
Jean-Charles Bocquet, ECPA

***Conference on endocrine disruptors: criteria for
identification and related impacts***

Brussels 1 June 2015

An industry viewpoint

Several sectors affected by criteria for endocrine disruptors: producers and downstream users

- For all sectors human health and environmental safety is a key priority
- Robust risk assessments are performed: to evaluate all effects, including potential for endocrine disruption
- Our commitment to stewardship



The big picture

• Endocrine active substances, endocrine disruptors

- Many substances with endocrine activity
- The criteria should focus on substances of regulatory concern
- Risk assessment needs to evaluate many elements to ensure safety
- Potential for endocrine disruption is but one of the many aspects to be assessed

The legislative picture

Our sectors are strictly regulated

- Objective of regulatory framework is to ensure products are safe and used in a responsible manner
- Products not considered safe are removed from the market
- Potential for endocrine disruption is already legislated and tested for (R&D phase + regulatory requirements)



The legislative picture

Mammalian tox (*in vivo*) studies typically included in regulatory dossiers

OECD Conceptual Framework: Level 4 and 5 (mammalian toxicology)

Repeated dose 28-day study (OECD TG 407)

Repeated dose 90-day study (OECD TG 408) (2 species)

Prenatal developmental toxicity study (OECD TG 414) (2 species)

Chronic toxicity and carcinogenicity studies (OECD TG 451-453)

Developmental neurotoxicity (OECD TG 426)

Extended one-generation reproductive toxicity study (OECD TG 443)

2-Generation reproduction toxicity study (OECD TG 416)

* There are over 40 assays and test guidelines available for mammalian toxicology and ecotoxicology contained in the OECD Conceptual Framework for Testing and Assessment of Endocrine Disruptors

Looking at the impact

Do we understand the impact of fewer products?

- Impact on health and food safety?
- Impact on innovation? Do we want innovation in EU?
- Impact on ability to manage new pests?
- Ability to manage resistance to pests and diseases?
- Impact on PPP use?

Do we really understand the big picture?

- Commission impact assessment should be comprehensive to support final policy decision

Hazard – and risk?

• We need to understand the hazard and risk

- Case example: Vitamin D3


• What are the risks of hazard based legislation?

- Failure to consider exposure (dose) can result in focusing on substances of little/no regulatory concern



Conclusion

- Human health and environmental safety is a key priority
- We have regulation and robust risk assessment in place
- Understanding and regulating potential for endocrine disruption is important
- But we need to understand the full impact of the criteria





THANK YOU